Compare KeyCorp (KEY) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KeyCorp vs Organon & Co. Common Stock — how do they compare? KeyCorp trades at $19.83 (market cap $21.25B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: KeyCorp is far larger — about 5.9× Organon & Co. Common Stock's market cap, and KeyCorp pays the higher dividend (4.12%). Which is the better fit depends on your goals — on Pluang, investors hold KeyCorp for 66 Days and Organon & Co. Common Stock for 0 Days on average.
| KEY | OGN | |
|---|---|---|
Market Cap | $21.25B | $3.62B |
Volume | 17,676,934 | 2,892,999 |
Sector | Financials | Health |
52-Week High | $23.99 | $13.81 |
52-Week Low | $16.78 | $5.70 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $34.43B | $11.04B |
Dividend Yield | 4.12% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KeyCorp (KEY) trades at $19.79, down 1.49% on the day, with a bearish technical signal but strong fundamentals including a P/E of 11.64 and net income margin of 26.72%. Recent quarterly earnings have consistently beaten expectations, and the company maintains a $0.21 dividend. Analyst consensus is bullish with a $25.00 price target, though recent news highlights competitive dividend pressures.
The outlook for KEY is positive based on earnings momentum and valuation, but risks include interest rate sensitivity and frozen dividends. Upside potential exists if loan growth and fee income continue to drive revenue, yet investor sentiment is cautious amid technical weakness and macroeconomic uncertainty.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
